343 related articles for article (PubMed ID: 20565377)
1. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report.
Keles M; Yildirim R; Uyanik A; Turkmen M; Bilen Y; Aydinli B; Cetinkaya R; Polat KY
Exp Clin Transplant; 2010 Jun; 8(2):181-3. PubMed ID: 20565377
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
3. A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil.
Royer B; Zanetta G; Bérard M; Davani S; Tanter Y; Rifle G; Kantelip JP
Clin Transplant; 2003 Apr; 17(2):158-61. PubMed ID: 12709084
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil.
Molina Perez E; Fernández Castroagudín J; Seijo Ríos S; Mera Calviño J; Tomé Martínez de Rituerto S; Otero Antón E; Bustamante Montalvo M; Varo Perez E
Transplant Proc; 2009 Apr; 41(3):1047-9. PubMed ID: 19376423
[TBL] [Abstract][Full Text] [Related]
6. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
[TBL] [Abstract][Full Text] [Related]
7. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant.
Savvidaki E; Kazakopoulos P; Papachristou E; Karavias D; Zavvos V; Voliotis G; Kalliakmani P; Marangos M; Goumenos DS
Exp Clin Transplant; 2014 Feb; 12(1):31-6. PubMed ID: 24471721
[TBL] [Abstract][Full Text] [Related]
8. Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor.
Becker-Cohen R; Ben-Shalom E; Rinat C; Feinstein S; Geylis M; Frishberg Y
Pediatr Nephrol; 2015 Nov; 30(11):2029-36. PubMed ID: 25994524
[TBL] [Abstract][Full Text] [Related]
9. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients.
Turgeon N; Hovingh GK; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):15-21. PubMed ID: 11429005
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
[TBL] [Abstract][Full Text] [Related]
12. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
13. Successful Cost-Effective Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients Using Low-Dose Valganciclovir.
Gheith O; Halim MA; Al-Otaibi T; Mansour H; Mosaad A; Atteya HA; Zakaria Z; Said T; Nair P; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):156-163. PubMed ID: 28260458
[TBL] [Abstract][Full Text] [Related]
14. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
15. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients.
Peddi VR; Hariharan S; Schroeder TJ; First MR
Clin Transplant; 1996 Feb; 10(1 Pt 1):20-3. PubMed ID: 8652892
[TBL] [Abstract][Full Text] [Related]
16. Treatment of neutropenia in a renal transplant recipient with granulocyte colony-stimulating factor.
Moghal NE; Milford DV; Darbyshire P
Pediatr Nephrol; 1998 Jan; 12(1):14-5. PubMed ID: 9502559
[TBL] [Abstract][Full Text] [Related]
17. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
18. Management of leukopenia in kidney and pancreas transplant recipients.
Hartmann EL; Gatesman M; Roskopf-Somerville J; Stratta R; Farney A; Sundberg A
Clin Transplant; 2008; 22(6):822-8. PubMed ID: 19040562
[TBL] [Abstract][Full Text] [Related]
19. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
[No Abstract] [Full Text] [Related]
[Next] [New Search]
